Biocon Ltd is one of India’s largest and most respected biopharmaceutical companies. Founded in 1978 by Kiran Mazumdar Shaw, it began as a small enzyme manufacturing company and has since transformed into a global healthcare player. Today, Biocon products focuses on developing and delivering affordable, high-quality medicines for chronic diseases such as diabetes, cancer, and autoimmune disorders, serving patients across 120+ countries.
Business segments
A. Generics (Biocon Limited)
The Generics division of Biocon Limited focuses on manufacturing active pharmaceutical ingredients (APIs) and finished generic drugs across key therapeutic areas such as cardiology, diabetes, obesity, immunosuppressants, and specialty medicines. The business continues to strengthen its global pipeline, with notable product launches like Liraglutide (a GLP-1 therapy) for diabetes and obesity in the UK. With regulatory filings underway, the company is now preparing for entry into the highly regulated US and EU markets.
B. Biosimilars (Biocon Biologics)
Biocon Biologics is a fully integrated global biosimilars company dedicated to developing affordable alternatives to expensive biologic drugs used in cancer, autoimmune diseases, and diabetes. Its strong portfolio includes market-leading products such as Fulphila (Pegfilgrastim) for cancer care, Ogivri (Trastuzumab) for breast cancer, Semglee (Insulin Glargine) for diabetes, and the recently launched Yesintek (Ustekinumab) for autoimmune diseases in the US. With a presence in over 120 countries, Biocon Biologics is now ranked among the top global players in the biosimilars space.
C. Research Services (Syngene International)
Through Syngene International, Biocon india operates a leading Contract Research & Development Manufacturing Organization (CRDMO) that collaborates with global pharmaceutical and biotechnology companies. Its service offerings span drug discovery, development, and commercial manufacturing. Syngene has also strengthened its global presence with the recent acquisition of a biologics manufacturing facility in the US, enabling greater capacity and expanding its ability to support clients across the product lifecycle.
D. Novel Biologics pipeline
Biocon company commitment to research-driven innovation is reflected in its Novel Biologics pipeline, which focuses on developing breakthrough therapies for complex diseases. These biologics aim to provide new treatment options where conventional drugs or existing biologics fall short.
Note: The small “Novel Biologics pipeline” segment (like other income and corporate income) is reported separately in financials but is not considered a full-fledged vertical because it doesn’t yet operate at the same scale.
Also read : Senores Pharma Capitalizing on CDMO Tailwinds for Global Ascent
Scale & global presence
Biocon is among the few Indian companies with deep expertise in biotechnology. It is renowned for producing high-quality yet affordable medicines, which makes advanced therapies accessible to patients in both emerging and developed markets. With a strong focus on biosimilars (cost-effective alternatives to expensive biologic drugs) and complex generics, Biocon operates in areas that many pharmaceutical companies find difficult to enter, further strengthening its competitive edge.
Biocon has established itself as a truly global biopharmaceutical company with a strong presence across key international markets. The company operates in over 120 countries, including major markets such as the United States, Europe, and several high-potential emerging economies. Its global footprint is supported by state-of-the-art manufacturing facilities in India, Malaysia, and the United States, all of which are approved by stringent regulatory agencies like the US FDA and EMA, ensuring world-class quality standards.
In FY25, Biocon reported a consolidated revenue of ₹16,469.9 crore, with its three verticals contributing significantly: Biosimilars (58%), Research Services (23%), and Generics (19%). This diversified revenue mix reflects the company’s strength across multiple therapeutic areas and business models.
The company serves millions of patients worldwide, with over 21 million patients benefiting from its medicines in FY25 alone. Biocon also has a great talent pool of 16,500+ employees, working across research through its biocon research limited, manufacturing, quality, and commercial functions, which fuels its innovation and operational excellence.
With a presence in both developed and developing markets, Biocon is well-positioned to cater to global healthcare needs. Its expanding global supply chain, strategic acquisitions, and collaborations with leading healthcare organizations have further strengthened its ability to deliver high-quality, affordable medicines worldwide.
Also read : BLS International A Scalable Play on Visa and Citizen Services
Competitive advantage
Biocon is among the few Indian companies with deep expertise in biotechnology. It is renowned for producing high-quality yet affordable medicines, which makes advanced therapies accessible to patients in both emerging and developed markets. With a strong focus on biosimilars (cost-effective alternatives to expensive biologic drugs) and complex generics, Biocon operates in areas that many pharmaceutical companies find difficult to enter, further strengthening its competitive edge.
Market position & competitors
Biosimilars: Competes with global players like Sandoz, Amgen, Viatris, but its India-based low-cost manufacturing gives it a significant advantage.
Generics: Competes with leading Indian and global generic players such as Sun Pharma, Teva, Dr. Reddy’s.
Research Services: Through Syngene, it competes with international CRDMO players like WuXi AppTec and Lonza, leveraging India’s cost advantage and scientific talent pool.
Financial Metrics
The bar chart represents the key financial metrics of Biocon Ltd over FY23, FY24, and FY25.
- Total Income shows a steady increase from ₹11,550 crores in FY23 to ₹16,470 crores in FY25.
- EBITDA also improved, rising from ₹2,889 crores in FY23 to ₹4,375 crores in FY25, reflecting stable operating performance.
- Profit for the Year moved up from ₹463 crores in FY23, peaked at ₹1,022 crores in FY24, and remained steady at ₹1,013 crores in FY25.
Overall, the graph shows consistent growth in revenue and operating profitability, with profits maintaining stability in the latest financial year.
Biocon’s segment-wise revenue
The bar chart represents the revenue contribution of Biocon Ltd.'s three key business segments over the last three financial years.
- Biosimilars is the largest revenue driver, growing sharply from ₹5,584 crores in FY23 to ₹9,017 crores in FY25, reflecting the strong global demand for its biologics portfolio.
- Generics revenue has grown steadily from ₹2,764 crores in FY23 to ₹3,018 crores in FY25, showing stable performance in the small-molecule business.
- Research & Services has also expanded, rising from ₹3,193 crores in FY23 to ₹3,642 crores in FY25, driven by contract research and development services located in biocon park.
Biosimilars segment has played a significant role in Biocon’s revenue growth while showing consistent contributions from Generics and Research & Services.
Growth strategy & opportunities
Biocon is well-positioned to capitalize on several high-growth areas:
- Expand biosimilars portfolio: Plan to launch 5 new biosimilars in the next 12–18 months, including Aspart (insulin), Aflibercept, and Denosumab.
- Focus on GLP-1 therapies: Entered the lucrative diabetes & obesity segment with Liraglutide, while building capabilities for Semaglutide and Tirzepatide, a market projected to reach USD 144 billion by 2029.
- Syngene growth: Leverage global outsourcing trends in drug research and manufacturing.
Capacity expansion: Ongoing investments in India and Malaysia to increase manufacturing for insulins, biosimilars, and injectables.
Risks & challenges
- Regulatory risks: Any delays or issues with US FDA or EMA inspections can impact product approvals.
- Pricing pressure: Particularly in the US and European generics/biosimilars markets, intense competition leads to price erosion.
- Debt: Net debt of approximately USD 1.1 billion as of March 2025, though the company is working on improving its balance sheet.
- Intense competition: Faces larger, more resourceful global competitors in all segments.
ESG & social Impact
Kiran Mazumdar Shaw in Biocon is deeply committed to sustainability and improving access to healthcare. In its India operations, 69% of the power consumed is sourced from renewable energy. The company also emphasizes efficient waste and water management, with 93% of its waste disposed of through circularity and 72% of water being recycled or reused. Biocon’s medicines positively impacted over 21 million patients in FY25, underscoring its healthcare reach. Additionally, the organization promotes workforce diversity, with women representing 27% of the workforce and board diversity exceeding 30% in some subsidiaries.
Also read : Assessing Valuation and Opportunity in Tata Chemicals
Why Biocon matters
Conclusion
Biocon Ltd has developed a diverse presence in biosimilars, generics, and research services, with operations spanning over 120 countries. Its revenue is driven primarily by biosimilars, supported by established generics and a growing CRDMO business through Syngene International. The company continues to invest in expanding its pipeline, global footprint, and manufacturing capabilities while navigating challenges such as regulatory requirements, pricing pressures, and competition.
Biocon Ltd continues to make waves in the market. Don’t miss out on the opportunities ahead. Start your trading journey with CubePlus today and stay in control of your investments. [Sign up now] and trade smarter.
Disclaimer: The information provided in our blogs is for informational purposes only and should not be construed as financial, investment, or trading advice. Trading and investing in the securities market carries risk. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Copyrighted and original content for your trading and investing needs.
© 2025 — Tradejini. All Rights Reserved.
